Related Experiment Video

Updated: May 11, 2026

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

Ascending monoaminergic systems alterations in Alzheimer's disease. translating basic science into clinical care

Ludwig Trillo1, Devsmita Das, Wayne Hsieh

  • 1Department of Physiology, School of Medicine, National University of San Agustin, Arequipa, Peru.

Neuroscience and Biobehavioral Reviews
|May 28, 2013
PubMed

Keywords:
3,4-Dihydroxyphenylacetic acid3-Methoxy-4-hydroxyphenylglycol5-HT5-HT transporter5-HT transporter gene-linked polymorphic region5-HTT5-HTTLPR5-Hydroxyindoleacetic acid5-Hydroxytryptamine5HIAAAADCACCADAPPARATMXAdrenergic receptorAlzheimer's diseaseAmnestic mild cognitive impairmentAmyloid precursor proteinAnterior cingulate cortexAβBDNFBPSDBehavioral/psychological symptoms in dementiaBrain-derived neurotrophic factorCACOMTCathechol-O-methyltranferaseCognition.Cornus ammonisDADA transporterDA β-hydroxylaseDA-ergicDATDBHDGDLPFCDOPACDRNDSDentate gyrusDopamineDopaminergicDorsal raphe nucleusDorsolateral prefrontal cortexDown syndromeECEntorhinal cortexG protein coupled receptorGPCRGWASGenome-wide association studiesHAHDCHMTHVAHistamineHistamine-N-methyl-transferaseHistidine decarboxylaseHomovanillic acidIDEIDOIndoleamine 2,3-dioxygenaseInsulin-degrading enzymeL-3,4-dihydroxyphenylalanineL-DOPAL-DOPSL-amino acid decarboxylaseL-threo-dihydroxyphenylserineLCLocus coeruleusMAMA-ergicMAOMAO-BMHPGMMSEMRNMSMedial septumMedian raphe nucleusMini-Mental State ExamMitochondrial DNAMonoamineMonoamine oxidaseMonoamine oxidase BMonoaminergicNADNADPNBMNFTNGFNerve growth factorNeurofibrillary tangleNicotinamide adenine dinucleotideNicotinamide adenine dinucleotide phosphateNorepinephrineOFCOrbitofrontal cortexPDPFCPLCPPParkinson's diseasePerforant pathPhospholipase CPrefrontal cortexSAMP8SNPSNpcSSRISelective serotonin reuptake inhibitorSenescence-accelerated prone mouseSerotoninSingle nucleotide polymorphismSubstantia nigra pars compactaTHTMNTPHTele-methylimidazole acetic acidTryptophan hydroxylaseTuberomamillary nucleusTyrosine hydroxylaseVMAVTAVanillylmandelic acidVentral tegmental areaaMCIamyloid βatomoxetinemtDNAnucleus basalis magnocellularist-MeHA

More Related Videos

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Long-term Depression01:03

Long-term Depression

Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over time, all...